Table of Contents
SGLT2 inhibitors are a class of medications primarily used to treat type 2 diabetes. They work by targeting a specific protein in the kidneys to help control blood sugar levels.
What Are SGLT2 Inhibitors?
SGLT2 inhibitors, also known as sodium-glucose co-transporter 2 inhibitors, are drugs that block the action of the SGLT2 protein. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream in the kidneys.
Mechanism of Action
Under normal conditions, the kidneys filter glucose out of the blood and then reabsorb most of it through the SGLT2 proteins in the proximal tubules. SGLT2 inhibitors prevent this reabsorption, leading to increased glucose excretion in the urine. This process helps lower blood glucose levels in people with diabetes.
By promoting glucosuria, SGLT2 inhibitors also contribute to a mild diuretic effect, which can lead to weight loss and blood pressure reduction.
Clinical Uses
SGLT2 inhibitors are primarily prescribed for managing type 2 diabetes mellitus. They are often used in combination with other antidiabetic medications to improve glycemic control.
Recent studies have shown additional benefits, including a reduction in the risk of cardiovascular events and hospitalization for heart failure in certain patient populations.
Common SGLT2 Inhibitors
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Ertugliflozin
Side Effects and Considerations
While effective, SGLT2 inhibitors can cause side effects such as urinary tract infections, genital infections, dehydration, and, rarely, ketoacidosis. Patients should be monitored regularly for adverse effects.
They are not recommended for use in patients with severe renal impairment or end-stage renal disease.
Conclusion
SGLT2 inhibitors represent a significant advancement in the treatment of type 2 diabetes, offering benefits beyond glycemic control. Understanding their mechanism of action helps clinicians optimize therapy and manage potential risks effectively.